Methyl Orange

Methyl Orange

SCHEMBL296472

CN(C)c1ccc(N=Nc2ccc(S(=O)(=O)O)cc2)cc1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.69
RAB9A P51151 4/20 0.69
KMT2A Q03164 4/20 0.69
CA12 O43570 4/20 0.69
CA2 P00918 4/20 0.69
CA9 Q16790 4/20 0.69
POLB P06746 3/20 0.69
MEN1 O00255 3/20 0.69
F2 P00734 3/20 0.64
PRSS1 P07477 3/20 0.64
PRSS2 P07478 3/20 0.64
PRSS3 P35030 3/20 0.64
CYP2D6 P10635 1/20 0.61
ALDH1A1 P00352 4/20 0.59
TSHR P16473 3/20 0.59
ALOX15 P16050 2/20 0.59
MAPK1 P28482 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 1/20 0.56
HSD17B10 Q99714 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Orange SCHEMBL296471 1.00 NPC1 (0.69) NPC1RAB9AKMT2ACA12CA2
Methyl Orange SCHEMBL16163325 1.00 NPC1 (0.69) NPC1RAB9AKMT2ACA12CA2
Methyl Orange SCHEMBL19662 0.98 NPC1 (0.67) NPC1RAB9AKMT2ACA12CA2
SCHEMBL1134428 0.88 ALDH1A1 (0.55) NPC1RAB9AKMT2ACA12CA2
SCHEMBL27333040 0.86 ALDH1A1 (0.53) NPC1RAB9AKMT2ACA12CA2
Hydrochloric Acid SCHEMBL28095718 0.86 ALDH1A1 (0.53) NPC1RAB9AKMT2ACA12CA2
SCHEMBL30364928 0.86 NPC1 (0.65) NPC1RAB9AKMT2ACA12CA2
SCHEMBL9019333 0.85 NPC1 (0.69) NPC1RAB9AKMT2ACA12CA2
SCHEMBL15631068 0.85 NPC1 (0.73) NPC1RAB9AKMT2ACA12CA2
SCHEMBL29829178 0.85 CA2 (0.51) NPC1RAB9AKMT2ACA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746853-A1 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2026-05-27 EP claimed
US-20260116796-A1 METHOD FOR RAPIDLY STARTING DYE-ORGANIC WASTEWATER ANAEROBIC CO-METABOLIC SYSTEM BASED ON S-NZVI NANJING UNIVERSITY (CN) 2026-04-30 US claimed
US-12590308-B1 Compositions and methods for suppressing intracellular synthesis of the beta subunit of human chorionic gonadotropin James Summerton Living Trust dated May 15, 2008 (US) 2026-03-31 US claimed
US-20260048382-A1 HYPER-CROSS-LINKED POLYAMIDE/POLYAMINE 3D-NETWORK FOR WATER TREATMENT KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-02-19 US claimed
US-20250339517-A1 LIPID NANOCARRIER VACCINE MELBOURNE INST TECH (AU) 2025-11-06 US claimed
WO-2025021835-A9 A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-11-06 WO claimed
WO-2025151305-A1 MEMORY DEVICE WITH ENHANCED THERMAL CONDUCTIVITY MICRON TECHNOLOGY, INC. (US) 2025-07-17 WO claimed
US-20250233044-A1 MEMORY DEVICE WITH ENHANCED THERMAL CONDUCTIVITY MICRON TECHNOLOGY, INC. 2025-07-17 US claimed
EP-4531812-A1 LIPID NANOCARRIER VACCINE Royal Melbourne Institute of Technology (AU) 2025-04-09 EP claimed
CN-119546282-A Lipid nanocarrier vaccine 皇家墨尔本理工大学 2025-02-28 CN claimed
CN-114073982-A Synthesis method of zinc oxide and perylene bisimide composite photocatalytic material with excellent photocatalytic performance under sunlight illumination 新疆大学 2022-02-22 CN claimed
US-20220026773-A1 MULTICOLOR, SINGLE ACTIVE LAYER ELECTROCHROMIC DEVICES UNIVERSITY OF SOUTH FLORIDA (US) 2022-01-27 US claimed
WO-2017161407-A1 OXIDANT SENSOR UNIVERSITY OF SOUTH AUSTRALIA (AU) 2017-09-28 WO claimed
EP-0778023-B1 Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. WYETH CORP (US) 2003-03-12 EP claimed
EP-1284828-A2 PROCESS FOR COATING POLYMERIC SUBSTRATES AND RESULTANT COATINGS 3M Innovative Properties Company (US) 2003-02-26 EP claimed
US-6511701-B1 Coatings and methods 3M INNOVATIVE PROPERTIES COMPANY 2003-01-28 US claimed
WO-2001085361-A2 PROCESS FOR COATING POLYMERIC SUBSTRATES AND RESULTANT COATINGS 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-11-15 WO claimed
EP-0778023-A1 Neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-11 EP claimed
US-5618726-A DYE HAVING LIGNIN-LIKE SUBSTITUTION PATTERN AND A MICROBE CAPABLE OF PRODUCING EXTRACELLULAR PEROXIDASE IDAHO RESEARCH FOUNDATION, INC. (US) 1997-04-08 US claimed
WO-1992017550-A1 BIODEGRADABLE AZO DYES IDAHO RESEARCH FOUNDATION, INC. (US) 1992-10-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590308-B1 Compositions and methods for suppressing intracellular synthesis of the beta subunit of human chorionic gonadotropin RNGTT, GNRHR, IGF2BP3 NPC1 2523/4885RAB9A 4062/4885KMT2A 3895/4885
US-20260116796-A1 METHOD FOR RAPIDLY STARTING DYE-ORGANIC WASTEWATER ANAEROBIC CO-METABOLIC SYSTEM BASED ON S-NZVI NDUFS6, SDHB, SORD NPC1 3040/4885RAB9A 2362/4885KMT2A 3932/4885
US-20260048382-A1 HYPER-CROSS-LINKED POLYAMIDE/POLYAMINE 3D-NETWORK FOR WATER TREATMENT H1-3, TET3, PAM NPC1 4664/4885RAB9A 2033/4885KMT2A 19/4885
US-20250339517-A1 LIPID NANOCARRIER VACCINE CD47, LY96, TSG101 NPC1 68/4885RAB9A 757/4885KMT2A 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.